Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study

Kardiologiya

Volumn 46, Issue 7, 2006, Pages 33-51

  Skvortsov, A A ^a   Nasonova, S N ^a   Sytchev, A V ^a   Orlova, Ya A ^a   Baklanova, N A ^a   Masenko, V P ^a   Mareev, V Yu ^a   Belenkov, Yu N ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Heart failure; Quinapril; Treatment; Valsartan

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; NORADRENALIN; QUINAPRIL; TETRAHYDROISOQUINOLINE DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMBINATION; EXERCISE TOLERANCE; FEMALE; FORWARD HEART FAILURE; HEART RATE; HEART VENTRICLE REMODELING; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; EXERCISE TOLERANCE; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; RECEPTORS, ANGIOTENSIN; TETRAHYDROISOQUINOLINES; TETRAZOLES; TREATMENT OUTCOME; VALINE; VENTRICULAR REMODELING;

EID: 33748858851     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Serneri G.G.N., Boddi M., Cecioni I. et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circulat Res 2001;88:961-968.
2. Petrie M.C., Padmanabhan N., McDonald J.E. et al. Angiotensin-converting enzyme (ACE) and non-ACE dependent angiotensin 11 generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001;37:1056-1061.
3. Jorde U.P., Ennezat P. V., Lisker J. et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-846.
4. Urata H., Healy B.H., Stewart R. et al. Angiotensin II forming pathways in normal and failing human hearts. Circulat Res 1990;66:883-890.
5. Witherow F.N., Helmy A., Webb D.J. et al. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 2001;104:2177-2181.
6. Witherow F.N., Dawson P., Ludlam C.A. et al. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol 2002;40:961-966.
7. McKelvie R.S., Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 1999;100:1056-1064.
8. Pitt B., Poole-Wilson P.A., Segal R. et al. on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
9. Pitt B., Segal R., Martinez F.A. et al. on behalf of the ELITE investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Eldery Study, ELITE). Lancet 1997;349:747-752.
10. Houghton A.R., Harrison M., Cowley A.G., Hampton J.R. Combined treatment with losartan and an ACE inhibitor in mild to moderate heart failure: results of double-blind, randomized, placebo-controlled trial. Am Heart J 2000;140:791-797.
11. Baruch L., Anand I., Cohen I.S. et al. for the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999;99:2658-2664.
12. Vescovo G., Libera L.D., Serafini F. et al. Improved exercise tolerance after losartan and enalapril in heart failure. Correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998;98:1742-1749.
13. Willenheimer R., Helmers C., Pantev E. et al. for the Heart Failure Valsartan Exercise capacity Evaluation (HEAVEN) Study Group. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol 2002;85:261-270.
14. Dickstein K., Chang P., Willenheimer R. et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-445.
15. Vaile J.C., Chowdhary S., Osman F. et al. Effects of angiotensin II (ATI) receptor blocade on cardiac vagal control in heart failure. Clin Sci 2001;101:559-566.
16. De Tommasi E., Iacoviello M., Romito R. et al. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 2003;146:e17.
17. Pfeffer M.A., McMurray J.J.V., Velazquez E.J. et al. for the Valsartan in Acute Myocardial Infarction (VALIANT) Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
18. Tang W.H., Vagelos R.H., Yee Y.G. et al. Neurohormonal and clinical responses to high-versus low-doses enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:70-78.
19. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998;19:481-489.
20. Nanas J.N., Alexopoulos G., Anastasiou-Nana M.I. et al. High Enalapril Dose Study Group. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol 2000;36:2096-2097.
21. Cohn J.N., Tognoni G. for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
22. Packer M. The neurohormonal hypothesis. A theory explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248.
23. Francis G.S., Benedict C., Johnstone D.E. et al. Comparison of neuroendocrine activation in patients with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724.
24. Dzau V.J., Hirch A.T. Emerging role of the tissue renin-angiotensin systems in congestive heart failure. Eur Heart J 1990;11:65-71.
25. Dzau V.J. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Bas Res Cardiol 1993;88:1-14.
26. Houghton A.R., Harrison M., Cowley A.G., Hampton J.R. Assessing exercise capacity, quality of life and haemodynamics in heart failure: do the tests tell us the same thing? Eur J Heart Fail 2002;4:289-295.
27. Massie B.M. Exercise tolerance in congestive heart failure: role of cardiac function, peripheral blood flow and muscle metabolism, and effect of treatment. Am J Med 1988;84:Suppl 3A:75-82.
28. Florea V.G., Mareyev V.Y., Achilov A.A. et al. Central and peripheral components of chronic heart failure: determinants of exercise tolerance. Int J Cardiol 1999;70:1:51-56.
29. Kinugava T., Tomikura Y., Ogino K. et al. Relation between neurohormonal activation and enhanced ventilatory response to exercise in patients with chronic congestive heart failure. Am J Cardiol 2001;89:604-607.
30. Chauhan A., Sridhar G., Clemens B. et al. Role of respiratory function in exercise limitation in chronic heart failure. Chest 2000;118:53-60.
31. Jondeau G., Dubourg D.J.C., Bourdarias J.P. Relation of functional improvement in congestive heart failure after quinapril therapy to peripheral limitation. Am J Cardiol 1997;79:5:635-638.
32. Guazzi M., Agostoni P., Guazzi M.D. Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. J Am Coll Cardiol 2001;37:398-406.
33. Metra M., Cas L.D., Panina G., Visioli O. Exercise hyperventilation in chronic congestive heart failure, and its relation to functional capacity and hemodynamics. Am J Cardiol 1992;70:622-628.
34. Ponikowski P.P., Chua T.P., Francis D.P. et al. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation 2001;104:2324-2330.
35. Ponikowski P.P., Uhua T.P., Piepoli M. et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation 1997;96:2586-2594.
36. Witte K.K.A., Thackray S.D.R., Nikitin N.P. et al. The effects of α and β-blockade on ventilatory responses to exercise in chronic heart failure. Heart 2003;89:1169-1173.
37. Eichorn E.J., Bristow M.R. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-2296.
38. Konstan M.A., Patten R.D., Thomas I. et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000;139:1081-1087.
39. Sanada S., Kitakaze M., Node K. et al. Differential subcellular actions of ACE inhibitors and ATI receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats. Hypertension 2001;38:404-409.
40. Dunselman P.H.J.M. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol 2001;77:131-138.
41. Biais C.Jr., Marceau F., Rouleau J.L. et al. The kallikrein-kininogen- kinin system: lessons from the quantification of endogenous kinins. Peptides 2000;21:1903- 1940.
42. Emanueli C., Maestri R., Corradi D. et al. Dilated and failing cardiomyopathy in bradykinin B, receptor knockout mice. Circulation 1999;100:2359-2365.
43. Liu Y.H., Yang X.P., Sharov V.G. et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-1935.
44. Bove C.M., Yang Z, Gilson W.D. et al. Nitric oxide mediates benefits of angiotensin II type 2 receptor overexpression during post-infarct remodeling. Hypertension 2004;43:680-687.
45. Liu Y.H., Yang X.P., Shesely E.G. et al. Role of angiotensin 2 type 2 receptors and kinins in the cadioprotective effect of angiotensin II type 1 receptor antagonists in rat with heart failure. J Am Coll Cardiol 2004;43:1473-1480.
46. Murdoch D.R., McDonagh T.A., Farmer R. et al. ADEPT: addition of the ATi receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and eurohormonal effects. Am Heart J 2001;141:800-807.
47. Wong M., Staszaewsky L., Latini R. et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. J Am Coll Cardiol 2004;43:2022-2027.
48. Lee A.F.C., Mac Fadyen R.J., Struthers A.D. Neurohormonal reactivation in heart failure patients n chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999;1:401-406.
49. Sigurdsson A., Swedberg K., Ullman B. Effects of ramipril on the neurohormonal response to exercise in patients with mild to moderate congestive heart failure. Eur Heart J 1994;15:247-254.
50. Jansson K., Dahlstrom U., Karlberg B.E. et al. The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. J Intern Med 1999;245:5:435-443.
51. Brunner-La Rocca H.P., Weilenmann D., Kiowski W. et al. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 1999;138:4:654-662.
52. van Veldhuisen D.J., Genth-Zotz S., Brouwer J. et al. High-versus low-dose ACE inhibition in chronic heart failure. A double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998;32:1811-1818.
53. Farguharson C.A., Struthers A.D. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-775.
54. Packer M., Poole-Wilson P.A., Armstrong P.W. et al. on behalf of the ATLAS study group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-2318.
55. McMurray J.J.V., Ostergren J., Swedberg K. et al. for the CHARM investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771.
56. Staessen J., Lijnen P., Fagard P. et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-465.
57. Borghi C., Boschi S., Ambrosioni E. et al. Evidence of a partial escape of renin-angiotensin-aldosterone blocade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-45.
58. Xiu J.C., Wu P., Xu J.P. et al. Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone. J Endocrinol Invest 2002;25:463-468.
59. Riegger G.A.J., Bouio H., Petr P. et al. for the Symptoms. Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999;100:2224-2230.
60. Cohn J.N., Anand I.S., Latini R. et al. for the Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Results from Valsartan Heart Failure Trial. Circulation 2003;108:1306-1309.
61. Skvortsov A.A., Mareev V.Yu., Naumov V.G., Belenkov Yu.N. Interactions between renin-angiotensin-aldosterone system and atrial natriuretic peptide in patients with congestive heart failure. Results with acute test with captopril. Second International Symposium on ACE Inhibition. London 1991:Abstr:52.
62. Houghton A.R., Harrison M., Cowley A.J. Haemodynamic, neurohumoral and exercise effects losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Eur J Heart Fail 1999;1:385-393.
63. Christensen G., Aksnes G., Ilebekk A., Kill F. Realese of atrial natriuretic factor during selective α- and β-adrenergic Stimulation, intracoronary Ca infusion and aortic constriction in pigs. Circulat Res 1991;68:638-644.
64. Latini R., Masson S., Anand I. et al. for the Val-HeFT Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. Circulation 2002;106:2454-2458.
65. Antonaccio M.J., Kerwin L. Pre- and postjunctional inhibition of vascular sympathethic function by captopril in SHR: implication of vascular angiotensin-II in hypertension and antihypertensive actions of captopril. Hypertension 1981;3:Suppl 1:1-54-1-62.
66. Grossi G., Cattaneo B.M., Seravalle G. et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997;96:1173-1179.
67. Eriksson S.V., Eneroth P., Kjekshus J. et al. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Clin Cardiol 1994;17:11:603-606.
68. Rundqvist B., Eisenhofer G., Elam M., Friberg P. Attenuated cardiac sympathetic responsiveness during dynamic exercise in patients with heart failure. Circulation 1997;95:940-945.
69. Zhu G.-Q., Patel K.P., Zucker I.H., Wang W. Microinjection of ANGII into paraventricular nucleus enhances cardiac sympathetic afferent reflex in rats. Am J Physiol Heart Circulat Physiol 2002;282:H2039-H2045.
70. Lia J.L., Zucker I.H. Regulation of sympathetic nerve activity in heart failure. A role for nitric oxide and angiotensin II. Circulat Res 1999;84:417-423.
71. Campese V.M., Ye S., Zhong H. Downregulation of neuronal nitric oxide synthase and interleukin-1β mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 2002;39:2:519-524.
72. Mitrovic V., Willenbrock R., Miric M. et al. on behalf of the study investigators. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am Heart J 2003;145:e14.
73. Brunner-La Rocca H.P., Esler M.D., Jennings G.L., Kaye D.M. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001;22:1136-1143.
74. Tygesen H., Rundquist B., Waagstein F., Wennerblom B. Heart rate variability measurement correlates with cardiac norepinephrine spillover in congestive heart failure. Am J Cardiol 2001;87:1308-1311.
75. Thomas G.P., Ferrier G.R., Howlett S.E. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in stimulated ventricular ischemia and reperfusion. J Pharm Exp Ther 1996;278:1090-1097.
76. Nolan J., Batin P.D., Andrews R. et al. Prospective study of heart rate variability and mortality in chronic heart failure. Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-Heart). Circulation 1998;98:1510-1516.
77. Bilchick K.C., Fetis B., Djoukend R. et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). Am J Cardiol 2002;90:24-28.
78. Townend J.N., West J.N., Davies M., Littler W.A. Effect of quinapril on blood pressure and heart rate in congestive heart failure. Am J Cardiol 1992;69:1587-1590.
79. Zhang Y., Sang Y., Zhu J. Effects of enalapril on heart rate variability in patients with congestive heart failure. Am J Cardiol 1995;76:1045-1048.
80. Murakami H., Liu J.L., Zucker I.H. Blockade of ATI receptors enhances baroreflex control of heart rate in conscious rabbits with heart failure. Am J Physiol 1996;271:R303-R309.
81. Heusser K., Vitkovsky J., Schmieder R.E., Schobel H.P. ATI antagonism by eprosartan lowers heart rate variability and baroreflex gain. Auton Neurosci 2003;107:45-51.
82. Morgan T., Griffiths C., Delbridge L. Low doses of angiotensin converting enzyme inhibitors and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive. Am J Hypertens 2002;15:1003-1005.